BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. APRE, a biopharmaceutical company focused on the development of novel synthetic lethality-based cancer therapeutics that target DNA damage response (DDR) pathways, announced today that the abstract titled “ATRN-W1051, a Novel and Potent WEE1 Inhibitor for Treatment of CCNE1-Overexpressing Ovarian Cancer” will be presented at the 14th Biennial Virtual Ovarian Cancer Research Seminar Series presented by the Rivkin Center and the American Association for Cancer Research (AACR). The series will take place on September 21, 22, 28, and 29, 2022, with each day scheduled to run from 12:00 p.m. to 2:00 p.m. US Pacific Time.
“A growing body of scientific evidence provides exciting development opportunities for our WEE1 inhibitor ATRN-W1051,” said Oren Gilad, Ph.D., Aprea’s President and Chief Executive Officer. “ATRN-W1051 is designed to be a potent and selective WEE1 inhibitor with a differentiated structure and potentially beneficial pharmacokinetic properties. The data presented demonstrate antiproliferative activity against a variety of cancer cell lines and inhibition of tumor growth in a genetically defined ovarian cancer xenograft model. We look forward to completing the IND-enabling studies and plan to start the clinical program shortly thereafter.”
A copy of the poster is available through the “Calendar of Events” in the “News and Events” section of the Apra website.
About Apra Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts, with research facilities in Doylestown, Pennsylvania, focused on the development of novel synthetic lethality-based cancer therapeutics that target DNA damage pathways. The Company’s lead program is ATRN-119, a phase 1-ready small molecule ATR inhibitor being developed for solid tumor indications. ATRN-W1051, the Company’s novel WEE1 inhibitor, is in preclinical development. For more information, please visit the company…
